Baird raises Abbott Laboratories stock target from USD 121.00 to USD 123.00

Published on 10/27/2026 at 10:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Abbott reported USD 13.01 billion in third-quarter sales. Abbott Laboratories stock costs EUR 93.59 on October 27, 2026, 0.14 percent above Xetra close.

Target and results

Robert W. Baird raised its Abbott target from USD 121.00 to USD 123.00 on October 22, 2026.
Third-quarter sales reached USD 13.01 billion on October 21, 2026, up 14.5 percent.
Abbott Laboratories stock trades at EUR 93.59 at 10:45 a.m. CET at Lang & Schwarz on October 27, 2026, 0.14 percent above the Xetra close of October 26, 2026.
Abbott declared a USD 0.63 dividend payable on November 16, 2026.

Abbott Laboratories, US0028241000, Illustration mit AI erstellt.

Abbott Laboratories (ISIN US0028241000) stock was trading at EUR 93.59 at Lang & Schwarz on October 27, 2026, at 10:45 a.m. CET. On October 22, 2026, Robert W. Baird raised its price target from USD 121.00 to USD 123.00 while maintaining an outperform rating, according to MarketBeat.

Quarterly growth meets guidance

Abbott reported third-quarter 2026 sales of USD 13.013 billion, up 14.5 percent from the year-earlier quarter, while comparable sales increased 7.0 percent. Adjusted diluted earnings per share reached USD 1.42, up 9.2 percent from USD 1.30 in the third quarter of 2025, according to Abbott.

The company tightened its full-year 2026 adjusted earnings-per-share guidance to USD 5.50-5.55 and reaffirmed the midpoint. The reported GAAP diluted earnings per share was USD 0.53, compared with USD 0.94 in the third quarter of 2025, as specified items included intangible amortization, legal settlements, acquisitions, restructuring and other expenses.

What does the target mean?

The target revision leaves Baird's USD 123.00 valuation above the US-listed share price of USD 104.88 at the October 26, 2026 quote, while the target change itself is a narrower signal than the quarterly operating figures. Abbott's third-quarter medical-device sales increased 6.9 percent on a reported basis and 7.8 percent on a comparable basis, with electrophysiology sales up 15.0 percent on a reported basis, according to Abbott.

Three dates shape the setup

The recent sequence began on September 17, 2026, when Abbott declared a USD 0.63 quarterly dividend. On October 21, 2026, it reported USD 13.013 billion in third-quarter sales. On October 22, 2026, Baird raised its target to USD 123.00 from USD 121.00, according to MarketBeat.

Which date comes next?

Abbott's declared dividend is payable on November 16, 2026, to shareholders of record at the close of business on October 15, 2026, according to Abbott.

Stock stays near the Xetra open

At EUR 93.59, the Lang & Schwarz quote stood EUR 0.13, or 0.14 percent, above the Xetra close of October 26, 2026 at EUR 93.46. Abbott's US listing was at USD 104.88 on October 26, 2026, while its 52-week range was USD 81.97 to USD 132.03 and its market capitalization was USD 181.5 billion.

The further course of trading is shown by the continuously updated real-time quote of Abbott Laboratories stock.